AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 95 filers reported holding AKERO THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,058,000 | -5.8% | 100,000 | -13.0% | 0.04% | -7.7% |
| Q2 2023 | $5,369,350 | +45.2% | 115,000 | +9.5% | 0.04% | +50.0% |
| Q1 2023 | $3,697,639 | -67.9% | 105,000 | -50.0% | 0.03% | -66.7% |
| Q4 2022 | $11,507,461 | +512.1% | 210,000 | +136.3% | 0.08% | +550.0% |
| Q4 2021 | $1,880,000 | -33.6% | 88,876 | -29.8% | 0.01% | -36.8% |
| Q3 2021 | $2,831,000 | -9.9% | 126,667 | 0.0% | 0.02% | -13.6% |
| Q2 2021 | $3,143,000 | +31.6% | 126,667 | +31.4% | 0.02% | +10.0% |
| Q1 2021 | $2,389,000 | -3.9% | 96,398 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $2,487,000 | -18.8% | 96,398 | -3.1% | 0.02% | -31.0% |
| Q3 2020 | $3,063,000 | -22.2% | 99,500 | -37.0% | 0.03% | -31.0% |
| Q2 2020 | $3,938,000 | +807.4% | 158,000 | +690.0% | 0.04% | +740.0% |
| Q1 2020 | $434,000 | -2.3% | 20,000 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $444,000 | -2.4% | 20,000 | 0.0% | 0.01% | -16.7% |
| Q3 2019 | $455,000 | +19.4% | 20,000 | 0.0% | 0.01% | +20.0% |
| Q2 2019 | $381,000 | – | 20,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
| COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
| Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
| Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
| Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
| Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
| Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
| Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |